# R-35 — Galderma Tri-Luma — Fluocinolone 0.01% / hydroquinone 4% / tretinoin 0.05%

The triple combination every compounded melasma formula is imitating, with the numbers the imitations do not publish: 38% and 13% completely cleared at eight weeks across two trials. The label calls it short-term, says melasma usually recurs, and refuses to be a maintenance product.

- **Canonical:** https://www.30plusskin.care/reviews/tri-luma-cream-review
- **Site:** 30+/SKIN — Skincare, published as a spec sheet.
- **Issue:** ISSUE NO. 13 / REV. 2026.10
- **Standing terms:** INDEPENDENT · AFFILIATE-FUNDED · NOT MEDICAL ADVICE

---

## Verdict

- **Stance:** RECOMMENDED — Buy it. The formula, the disclosure and the price all hold up.
- **Weighted score:** 85/100 across 75% of the scoring model
- **Score scope:** See assessed criteria
- **Category:** PRESCRIPTION MANUFACTURED / MELASMA
- **Price:** $294 — PER 30 G TUBE · SHORT-TERM COURSE
- **Container size:** 30 G
- **Prescription:** yes
- **Compounded:** no
- **Assessment basis:** DESK REVIEW
- **Last updated:** 2026-08-02
- **Manufacturer page:** https://www.galderma.com/us/products/tri-luma

This is the reference standard, and it is worth understanding precisely because eleven products in this register are compounded versions of it. Kligman's triple combination — a retinoid, hydroquinone and a mild corticosteroid — went through two controlled trials in 641 subjects and came out with an approval, a fixed set of concentrations and a published success rate. The concentrations are 0.01% fluocinolone acetonide, 4% hydroquinone and 0.05% tretinoin, printed on the carton in milligrams per gram.

The efficacy result is the number to carry around. Treatment success was defined strictly — melasma completely cleared, a severity score of zero — and at eight weeks it was reached by 38% of subjects in the first trial and 13% in the second. Both beat every two-drug combination tested against them in the same vehicle, which is the finding that established triple therapy as first line. Both are also a long way from the 74% to 91% satisfaction figures the compounded competition prints.

The label's honesty about duration is what earns the recommendation. Tri-Luma is indicated for short-term treatment, is explicitly not indicated for maintenance, states that therapy should be discontinued when control is achieved, and states that melasma usually recurs on stopping. Three of the four hydroquinone products we have reviewed are sold on open-ended monthly billing. This one is a course, and the label says where the course ends.

The cautions are real and they are all printed. It contains a corticosteroid, so it carries an HPA-axis suppression warning. It contains hydroquinone, so it carries an exogenous ochronosis warning that specifically notes most reported cases are in Black patients. It contains sodium metabisulfite, which can trigger anaphylaxis in susceptible people. Fitzpatrick V and VI were never studied. Sixty-three per cent of trial subjects had a treatment-related adverse event. None of that is hidden, and it is all information a compounded equivalent cannot give you.

## Actives, as published

| Active | Concentration | Role | Benchmark | Assessment | Flagged |
| --- | --- | --- | --- | --- | --- |
| Hydroquinone | 4% | Tyrosinase inhibitor — reduces melanin synthesis | 4% is the conventional prescription strength; 2% was the former over-the-counter ceiling | The concentration the evidence base is actually built on, and the one every safety review treats as the reference. Set this against the 12% compounded onto body-sized surface areas at R-01 and the 6% at R-07: the approved product, backed by two controlled trials, sits at 4%. | no |
| Tretinoin | 0.05% | Retinoid — increases epidermal turnover and enhances hydroquinone penetration | 0.025% to 0.1% across the trial literature | Squarely inside the trial range, and the component the two-drug comparator arms showed you cannot drop: fluocinolone plus hydroquinone without tretinoin cleared 4% and 1% of subjects in the two trials, against 38% and 13% for the full combination. | no |
| Fluocinolone acetonide | 0.01% | Low-potency corticosteroid — suppresses the irritation the other two cause, and contributes independently to depigmentation | 0.01% is a low-potency topical steroid concentration | The reason this is a short-term product. Topical steroids on facial skin over months produce atrophy, telangiectasia and perioral dermatitis, and the label carries an HPA-axis suppression warning. It is correctly dosed and correctly time-limited — and it is the component that makes selling this pattern on a rolling subscription indefensible. | yes |

## Scoring

| Criterion | Weight | Score | Note |
| --- | --- | --- | --- |
| EVIDENCE FOR THE ACTIVE | 30% | 88/100 | Two adequate and well-controlled trials, 641 subjects aged 21 to 75, with all three two-drug combinations tested in the identical vehicle as comparators — the design that isolates the contribution of each component. Success defined as complete clearing, not improvement. Marked down only because Fitzpatrick V and VI were excluded and both trials ran only eight weeks. |
| FORMULATION INTEGRITY | 20% | 84/100 | Fixed, manufactured, quality-controlled, with the three actives stated in milligrams per gram and a full excipient list. Hydroquinone is stabilised in a hydrophilic base. Marked down for sodium metabisulfite, a genuine anaphylaxis risk in sulfite-sensitive people, and because a fixed-dose combination cannot be titrated the way a compounded one can. |
| DISCLOSURE | 15% | 92/100 | Concentrations, fill weight, excipients, both trials including the weaker one, the comparator arms, the adverse event rate, the ochronosis warning naming the affected population, the HPA-axis warning, the sulfite warning, and an explicit limitation of use stating that this is not a maintenance product and that melasma usually recurs. Held back only because cost per course is left to the reader. |
| TOLERANCE IN USE | 15% | not scorable | Not assessed by us, though the label is unusually specific: 63% of subjects had at least one treatment-related adverse event, most commonly erythema at 41%, then desquamation, burning, dryness and pruritus, mostly mild to moderate. A panel would add tolerability over a full eight-week course, which is what patients actually need to know. |
| TEXTURE & WEAR | 10% | not scorable | Not assessed. A light yellow hydrophilic cream applied at night, so wear matters less here than in a daytime product. |
| COST PER APPLICATION | 10% | 64/100 | Around $294 for 30 g at retail, near $228 with a discount card, and frequently covered because melasma is a recognised medical indication. The fill weight is published, so cost per application is computable. It is expensive against generic triple-combination creams, but it is a finite course rather than a standing monthly charge — over a year that inverts the comparison with most subscription compounders. |

_A criterion that cannot be assessed from published information is not guessed at. Its weight is removed from the denominator, and the coverage figure above says how much of the model survived._

## Strengths

- All three concentrations printed on the carton, in per cent and in milligrams per gram.
- Two controlled trials with a strict endpoint — complete clearing, not self-reported improvement.
- Both two-drug comparator arms published, so the contribution of each component is visible.
- Publishes the weaker trial (13% success) alongside the stronger one (38%).
- Explicitly not indicated for maintenance, with instruction to discontinue when control is achieved.
- States plainly that melasma usually recurs after stopping.
- Carries the exogenous ochronosis warning and names the population most affected.
- Carries an HPA-axis suppression warning for the corticosteroid component.
- Declares sodium metabisulfite and its anaphylaxis risk.
- States that Fitzpatrick V and VI have not been studied, rather than implying they have.
- A prescription and a tube, not a subscription.

## Weaknesses

- Both trials ran only eight weeks, so nothing is known about a longer course from the registration data.
- Fitzpatrick V and VI were excluded, and the label concedes excessive bleaching in darker skin cannot be ruled out.
- 63% of trial subjects had a treatment-related adverse event; erythema alone affected 41%.
- Contains a topical corticosteroid, which is what forces the short-term limitation.
- Sodium metabisulfite is a real hazard for sulfite-sensitive patients.
- Around $294 retail for 30 g, against generic triple-combination creams at a fraction of that.
- Pregnant and lactating women were excluded from the trials, so there is no safety data for them.
- The label sets no maximum number of courses, so repeat prescribing is left entirely to the prescriber.

## Suits

- Someone with moderate to severe facial melasma who wants the combination that has actually been trialled, at the concentrations that were trialled.
- Someone who wants a defined course with a defined end rather than an indefinite monthly charge.
- Someone weighing a compounded melasma formula who wants the benchmark figures — 38% and 13% cleared at eight weeks — to compare it against.
- Someone who will use SPF 30 daily and avoid sun, which the label requires and both trials supplied.
- Someone whose prescriber will schedule a review and a stop, because the corticosteroid makes that necessary.

## Avoid if

- You are pregnant, planning pregnancy or breastfeeding — the trials excluded you and there is no data.
- You are sulfite-sensitive or asthmatic with sulfite sensitivity, because of the sodium metabisulfite.
- You want a maintenance treatment. This label says, in its own limitations of use, that it is not one.
- You have Fitzpatrick V or VI skin and want studied evidence, which does not exist for this product.
- You cannot commit to daily SPF 30 and sun avoidance, without which melasma treatment fails regardless of drug.
- You are looking for a product to treat hyperpigmentation that is not facial melasma — no other indication has been studied.

## The full assessment

### What it is

A fixed-dose triple combination cream — fluocinolone acetonide 0.01%, hydroquinone 4% and tretinoin 0.05% — approved for the short-term treatment of moderate to severe facial melasma, applied once daily at least thirty minutes before bed. A 30 g tube, around $294 at retail. It is the manufactured, trialled original of a formula that at least four telehealth compounders in this register sell variations of.

**RECORD**

| Field | Value |
| --- | --- |
| BRAND | GALDERMA |
| PRODUCT | TRI-LUMA CREAM |
| ACTIVES | FLUOCINOLONE 0.01% · HYDROQUINONE 4% · TRETINOIN 0.05% |
| STATED AS | 0.1 MG / 40 MG / 0.5 MG PER GRAM |
| APPROVAL | FDA APPROVED — NDA, NOT COMPOUNDED |
| INDICATION | SHORT-TERM TREATMENT OF MODERATE TO SEVERE MELASMA |
| TRIAL DURATION | 8 WEEKS · 2 TRIALS · N=641 |
| MAINTENANCE USE | EXPLICITLY NOT INDICATED |
| SIZE | 30 G — PUBLISHED |
| PRICE | ~$294 RETAIL · ~$228 DISCOUNTED |

### What treatment success actually means here

The primary endpoint in both trials was the investigator's assessment of treatment success, defined as a melasma severity score of zero — lesions cleared of hyperpigmentation. Not improved. Not lighter. Cleared.

**FIG. 1 — COMPLETE CLEARING AT 8 WEEKS, TRI-LUMA vs EACH TWO-DRUG PAIR** — Trial 1 and Trial 2, same vehicle throughout, investigator-assessed. HQ = hydroquinone 4%, RA = tretinoin 0.05%, FA = fluocinolone acetonide 0.01%. The three-drug combination beat all three pairs in both trials — and the two trials disagree with each other by a factor of three, which is why publishing both matters.

| Item | Value (% CLEARED) | Note |
| --- | --- | --- |
| TRI-LUMA — TRIAL 1 | 38 | 32 of 85 subjects cleared |
| HQ + RA — TRIAL 1 | 15 | 12 of 83 — no steroid |
| FA + HQ — TRIAL 1 | 4 | 3 of 85 — no retinoid |
| FA + RA — TRIAL 1 | 0 | 0 of 85 — no hydroquinone. Nothing cleared. |
| TRI-LUMA — TRIAL 2 | 13 | 10 of 76 subjects cleared |
| HQ + RA — TRIAL 2 | 4 | 3 of 75 |
| FA + RA — TRIAL 2 | 4 | 3 of 76 |
| FA + HQ — TRIAL 2 | 1 | 1 of 76 |

_Scale maximum: 40% CLEARED._

Three readings. First, the combination is genuinely better than its parts, and the pair without hydroquinone cleared nobody at all in trial 1 — hydroquinone is doing the work, and the other two are making it work harder. Second, 38% and 13% are the real ceiling for eight weeks of the best-evidenced melasma treatment there is. Third, the two trials differ by threefold on the same protocol, which is an honest indication of how variable melasma outcomes are and how little weight any single figure deserves.

> **NOW COMPARE THE FIGURES YOU HAVE BEEN SHOWN ELSEWHERE** — Compounded melasma and pigment products in this register advertise 74%, 79%, 80% and 91% — self-assessed, at day 30, by paying subscribers, with no control arm. Tri-Luma's investigator-assessed complete clearance at twice that duration is 38% in its better trial. Those are not competing results. They are different kinds of statement, and only one of them was measured against a group who got the vehicle.

### The limitation of use is the most valuable paragraph on the label

> TRI-LUMA Cream is NOT indicated for the maintenance treatment of melasma… Melasma usually recurs upon discontinuation of TRI-LUMA Cream.

> — FDA-approved labelling, Limitations of Use

Two admissions in one paragraph. This is a course, not a regimen — and when you stop, the melasma is likely to come back. The dosage section reinforces it: 'Therapy should be discontinued when control is achieved.'

The reason is the corticosteroid. Fluocinolone acetonide is low potency, but facial skin under a topical steroid for months develops atrophy, telangiectasia and perioral dermatitis, and systemic absorption can suppress the HPA axis. The steroid is in there to make 4% hydroquinone plus 0.05% tretinoin tolerable, and its presence is precisely what caps the duration.

Which is why the same three-drug pattern sold as a monthly subscription is a different product in the only sense that matters. The molecules can be identical. The default behaviour is not: a course defaults to stopping, and a subscription defaults to continuing.

### The warnings, in full

**WHAT THE LABEL DISCLOSES THAT A COMPOUNDED EQUIVALENT CANNOT**

| Field | Value |
| --- | --- |
| EXOGENOUS OCHRONOSIS | GRADUAL BLUE-BLACK DARKENING; MAJORITY OF CASES IN BLACK PATIENTS |
| HPA AXIS SUPPRESSION | REVERSIBLE; CUSHING'S, HYPERGLYCAEMIA, GLUCOSURIA POSSIBLE |
| SODIUM METABISULFITE | ANAPHYLAXIS AND LIFE-THREATENING ASTHMA IN SUSCEPTIBLE PEOPLE |
| SENSITISATION | 3 OF 221 VOLUNTEERS IN A PATCH TEST STUDY |
| TREATMENT-RELATED AE RATE | 102 OF 161 SUBJECTS — 63% |
| MOST COMMON AE | ERYTHEMA, 41% |
| FITZPATRICK V–VI | NOT STUDIED |
| PREGNANCY / LACTATION | EXCLUDED FROM TRIALS; NOT ESTABLISHED |

The ochronosis warning is worth dwelling on. It is the same risk that makes 12% compounded hydroquinone at R-01 a caution — and here it appears at 4%, in an approved product, with the affected population named. A compounded formula at three times this concentration carries at least this risk and none of this documentation.

### If you are considering it

- Get a stop date at the same appointment as the prescription. The label requires one; the pharmacy will not give you one.
- Expect eight weeks, applied nightly, thirty minutes before bed.
- Wear SPF 30 daily and avoid sun. Both trials supplied it and it is written into the dosing instructions.
- Ask what the maintenance plan is after the course, because the label deliberately does not provide one and melasma usually recurs.
- Tell the prescriber if you are sulfite-sensitive or asthmatic.
- If you have Fitzpatrick V or VI skin, ask specifically about the excessive-bleaching caution the label raises.
- If a bought-online compounded alternative is being weighed against this, ask it for its eight-week complete-clearance rate against a vehicle arm. It will not have one.

### Where we stand

At 85 this sits near the top of the register, and the reasons are unglamorous: it publishes its concentrations, it publishes both its trials including the disappointing one, it publishes what happened to the comparator arms, it names its risks and the populations they fall on, and it tells you to stop. It is the best-documented product we have assessed, which is a different claim from being the best product, and the more useful one.

The efficacy is not spectacular. Thirteen per cent cleared in the weaker trial is a sobering number for anyone who has been sold melasma treatment as a solved problem. But it is a real number, measured against a real control, at a stated duration, on a stated population — and every compounded triple-combination in this register is an unverified variation on it, usually at undisclosed strengths, usually on rolling monthly billing, usually advertising a self-reported figure five times larger.

**READ ALONGSIDE**

- [R-01 Musely The Body Cream](/reviews/musely-the-body-cream-review) — CAUTION 47/100 — Hydroquinone at 12% — three times this product's concentration, on body-sized surface areas.
- [R-26 Obagi Nu-Derm Clear](/reviews/obagi-nu-derm-clear-review) — CONDITIONAL 74/100 — The other manufactured hydroquinone product in the register.
- [L-06 A course is not a subscription](/ledger/a-course-is-not-a-subscription) — Why a label that says 'discontinue when control is achieved' is incompatible with rolling billing.

## Where to buy

| Retailer | Price | Link | Note | Commission-bearing |
| --- | --- | --- | --- | --- |
| Prescriber + retail pharmacy | ~$294 / 30 g | https://www.galderma.com/us/products/tri-luma | Prescription only. Frequently covered when prescribed for melasma. Generic triple-combination creams exist at lower cost. | no |

We earn nothing on this link. Ask the prescriber for a stop date at the same appointment you get the prescription — the label requires one and the pharmacy will not supply it.

**Featured alternative:** [CoreAge Rx Spot On](https://www.coreagerx.com/product/spot-on/?utm_source=30plusskin&utm_medium=affiliate&utm_campaign=review&utm_content=tri-luma-cream-review&utm_term=markdown) — Hydroquinone, kojic acid and niacinamide for dark spots. From $54.99 / month advertised.

## Sources

- [FDA-approved labelling — TRI-LUMA (fluocinolone acetonide, hydroquinone, and tretinoin) cream, Galderma Laboratories, L.P.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a35fa709-5eb5-4429-b38f-f1e0019bf0ee) — Strengths of 0.01%/4%/0.05% stated as 0.1 mg, 40 mg and 0.5 mg per gram; the limitations of use excluding maintenance and stating that melasma usually recurs; Table 2 treatment success (38% and 13% against the three two-drug comparators); the 641-subject two-trial programme; the ochronosis, HPA-axis and sodium metabisulfite warnings; the 63% treatment-related adverse event rate and 41% erythema; and the exclusion of Fitzpatrick V–VI and of pregnant and lactating women. Read 2 August 2026.
- [GoodRx — Tri-Luma pricing](https://www.goodrx.com/tri-luma) — Retail price of about $294.59 for the 30 g tube and a discounted price near $227.92. Retrieved 2 August 2026.

## Related records

- [R-16 Agency Dark Spot Rx](/reviews/agency-dark-spot-formula-review) — CONDITIONAL
- [L-18 Prescription skincare follow-up: what to establish before the first refill](/ledger/prescription-skincare-follow-up)
- [L-08 Ask what the vehicle arm did](/ledger/ask-what-the-vehicle-arm-did)
- [L-06 A course is not a subscription](/ledger/a-course-is-not-a-subscription)
- [L-05 Compounded is not approved](/ledger/compounded-is-not-approved)
- [R-01 Musely The Body Cream](/reviews/musely-the-body-cream-review) — CAUTION
- [R-26 Obagi Nu-Derm Clear](/reviews/obagi-nu-derm-clear-review) — CONDITIONAL
- [L-11 Before a compounded melasma prescription: five questions to ask](/ledger/compounded-melasma-questions)
- [R-66 Strut Health Melasma Formula](/reviews/strut-melasma-formula-review) — CAUTION

---

## PROMOTIONAL SPOTLIGHT: Explore CoreAge Rx skincare

More options for your skin. A patient community to connect with along the way.

**Five skincare options to explore** — Browse CoreAge Rx's prescription skincare range for concerns including fine lines, dark spots, blemishes and more.

**Connect with other patients** — Explore the CoreAge Rx patient community for shared experiences, conversations and support beyond your daily routine.

[CHECK OUT COREAGE RX SKINCARE](https://try.coreagerx.com/skincare?utm_source=30plusskin.care&utm_medium=affiliate&utm_campaign=skincare_reviews&utm_content=reading_footer)

[EXPLORE THE PATIENT COMMUNITY](https://community.coreagerx.com/)

[Read our CoreAge Rx reviews](/reviews/coreage-rx-skincare-review)

Prescription options require a clinician's assessment. Compounded medications are not FDA-approved. Community discussions do not replace medical advice.

[Product range](https://help.coreagerx.com/medication/coreage-rx-prescription-skincare) · [Community information](https://www.coreagerx.com/contact-us/)

[About promotional placements](/disclosure)

---

## Elsewhere in the register

- [Review register](/reviews)
- [Active monographs](/actives)
- [Brand register](/brands)
- [Evidence register](/evidence)
- [The ledger](/ledger)
- [How we test](/how-we-test)
- [Agent guide](/llms.txt)
- [Sitemap](/sitemap.xml)

_SOURCE-BASED ASSESSMENTS. PUBLISHER PREFERENCES ARE IDENTIFIED SEPARATELY._